SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

BioMerieux

Geschlossen

BrancheGesundheitswesen

121.4 1.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

120.8

Max

121.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.6M

217M

Verkäufe

785M

KGV

Branchendurchschnitt

32.582

51.198

Dividendenrendite

0.76

Gewinnspanne

10.438

Angestellte

14,147

EBITDA

161M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+8.71% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.76%

2.40%

Nächstes Ergebnis

4. Sept. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

461M

14B

Vorheriger Eröffnungskurs

120.32

Vorheriger Schlusskurs

121.4

Nachrichtenstimmung

By Acuity

17%

83%

29 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

BioMerieux Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Apr. 2025, 08:49 UTC

Wichtige Markttreiber

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Peer-Vergleich

Kursveränderung

BioMerieux Prognose

Kursziel

By TipRanks

8.71% Vorteil

12-Monats-Prognose

Durchschnitt 131 EUR  8.71%

Hoch 140 EUR

Tief 125 EUR

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMerieux – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

113.1 / 118.6Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

29 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.